IAMA Therapeutics is focused on advancing innovative treatments for neurological conditions, particularly autism and epilepsy, by leveraging breakthroughs in neuroscience and precision medicine. The company is developing a pipeline of small molecules aimed at selectively inhibiting cation-chloride cotransporters, specifically the sodium-potassium chloride cotransporter (NKCC1). This approach targets the signaling imbalances between excitation and inhibition in the brain, which are implicated in various central nervous system (CNS) disorders. By inhibiting NKCC1, IAMA Therapeutics aims to restore neuronal excitability and address the underlying pathophysiology of conditions such as autism spectrum disorder and drug-resistant epilepsy.

The lead program, IAMA-6, has shown promising efficacy in preclinical models and is currently undergoing a Phase 1 clinical study to evaluate its safety and pharmacokinetics. Additionally, IAMA Therapeutics is exploring other potential treatments, including IAMA-299 for cognitive impairment, and has established research collaborations to further develop selective NKCC1 inhibitors. The company’s commitment to addressing unmet medical needs in the CNS space underscores its mission to improve the lives of individuals affected by neurological disorders and their families.

Italy

IAMA Therapeutics is a late preclinical-stage pharmaceutical company raising a Series B to fund the clinical development of its lead candidate in epilepsy and neurodevelopment disorders. The Company’s lead candidate, IAMA-6, is a "best-in-class" selective NKCC1 inhibitor being developed for various orphan brain disorders, including drug-resistant epilepsy, and is expected to enter the clinic in October 2023. Other pipeline candidates include new molecular entities to target Cation Chloride Cotransporters in pediatric neuropsychiatric conditions.

IAMA Therapeutics

Company Details